US 11,938,058 B2
Ocular implant and delivery system
Andrew T. Schieber, St. Louis Park, MN (US); Charles L. Euteneuer, St. Michael, MN (US); David T. Van Meter, Laguna Beach, CA (US); and Kenneth M. Galt, Laguna Hills, CA (US)
Assigned to Alcon Inc., Fribourg (CH)
Appl. No. 16/061,671
Filed by Alcon Inc., Fribourg (CH)
PCT Filed Dec. 15, 2016, PCT No. PCT/US2016/066957
§ 371(c)(1), (2) Date Jun. 13, 2018,
PCT Pub. No. WO2017/106517, PCT Pub. Date Jun. 22, 2017.
Claims priority of provisional application 62/267,794, filed on Dec. 15, 2015.
Prior Publication US 2018/0369017 A1, Dec. 27, 2018
Int. Cl. A61F 9/007 (2006.01); A61B 3/16 (2006.01); A61M 5/00 (2006.01); A61M 25/00 (2006.01)
CPC A61F 9/00781 (2013.01) [A61B 3/16 (2013.01); A61M 5/00 (2013.01); A61M 25/00 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method for reducing intraocular pressure in a patient, the method comprising:
deploying an ocular implant adapted to reside at least partially in a portion of Schlemm's canal of an eye, the ocular implant comprising:
a tubular body having an inner surface and an outer surface, the tubular body extending in a curved volume whose longitudinal axis forms an arc of a circle; and
a plurality of open areas and strut areas formed in the tubular body, the strut areas surrounding the plurality of open areas; and
a pressure sensor disposed on the inner surface of the tubular body, wherein deployment of the ocular implant is configured to lower an intraocular pressure of the eye from an initial pretreatment pressure to a second pressure; and
administering a therapeutic agent comprising a Rho kinase (ROCK) inhibitor to the patient after the deployment of the ocular implant to lower the intraocular pressure to a third pressure lower than the second pressure, wherein the therapeutic agent comprising the Rho kinase (ROCK) inhibitor is administered to the patient using an eye dropper or a syringe.